SCPHARMACEUTICALS INC. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2025-10-07: Form 8-K; Period of report 2025-10-07; Description 1.02 Termination of a Material Definitive Agreement; 2.01 Completion of Acquisition or Disposition of Assets; 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing; 3.03 Material Modification to Rights of Security Holders; 5.01 Changes in Control of Registrant; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year; Details 1.02.
- 2025-09-24: Form 8-K; Period of report 2025-09-23; Description 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; Details 1.01.
- 2025-08-25: Form 8-K; Period of report 2025-08-24; Description 1.01 Entry into a Material Definitive Agreement; 7.01 Regulation FD Disclosure; Details 1.01.
- 2025-08-25: Form 8-K; Period of report 2025-08-20; Description 1.01 Entry into a Material Definitive Agreement; Details 1.01.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2025-10-07 | 8-K | 2025-10-07 | 1.02 Termination of a Material Definitive Agreement; 2.01 Completion of Acquisition or Disposition of Assets; 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing; 3.03 Material Modification to Rights of Security Holders; 5.01 Changes in Control of Registrant; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year | 1.02 The information contained in the Introductory Note and under Item 2.01 of this Current Report on Form 8-K is incorporated by reference into this Item 1.02. 2.01 The information set forth in the Introductory Note and Items 1.02, 5.01 and 5.03 of this Current Report on Form 8-K is incorporated by reference into this Item 2.01. 3.01 The information set forth in Item 2.01 of this Current Report on Form 8-K is incorporated by reference into this Item 3.01. 3.03 The information set forth under Items 2.01, 3.01, 5.01, and 5.03 of this Current Report on Form 8-K is incorporated by reference into this Item 3.03. 5.01 The information set forth under Items 2.01, 5.02, and 5.03 of this Current Report on Form 8-K is incorporated by reference into this Item 5.01. 5.02 The information set forth in Item 2.01 of this Current Report on Form 8-K is incorporated by reference into this Item 5.02. 5.03 Pursuant to the terms of the Merger Agreement, on October 7, 2025, the Company’s second amended and restated certificate of incorporation and amended and restated bylaws were each amended and restated in their entirety and, as so amended and restated, became the certificate of incorporation and bylaws of the Surviving Corporation. | d20686d8k.htm |
| 2025-09-24 | 8-K | 2025-09-23 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant | 1.01 On September 23, 2025, scPharmaceuticals Inc., a Delaware corporation (the “Company” or “scPharmaceuticals”), issued an unsecured promissory note (the “Company Promissory Note”) to MannKind Corporation, a Delaware corporation (“Parent”) in exchange for a loan of $10.0 million by Parent to the Company. 2.03 The information provided in Item 1.01 of this Current Report on Form 8-K is incorporated in this Item 2.03 by reference. | d62041d8k.htm |
| 2025-08-25 | 8-K | 2025-08-24 | 1.01 Entry into a Material Definitive Agreement; 7.01 Regulation FD Disclosure | 1.01 On August 24, 2025, scPharmaceuticals Inc., a Delaware corporation (the “Company” or “scPharmaceuticals”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) with MannKind Corporation, a Delaware corporation (“Parent”), and Seacoast Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Parent (“Purchaser”), pursuant to which Parent, through Purchaser will commence a tender offer (the “Offer”) to acquire all of the outstanding shares of the common stock, par value $0.0001 per share (the “Shares”), of the Company, at a price per share of (i) $5.35 in cash (the “Cash Amount”), without interest, subject to any applicable withholding taxes, and (ii) one non-tradeable contingent value right (each, a “CVR” and each CVR together with the Cash Amount, the “Offer Price”), which represents the right to receive certain milestone payments of up to an aggregate of $1.00 in cash. 7.01 On August 25, 2025, the Company and Parent issued a joint press release regarding the execution of the Merger Agreement. | d20370d8k.htm |
| 2025-08-25 | 8-K | 2025-08-20 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | d931746d8k.htm |
| 2025-08-07 | 8-K | 2025-08-07 | 2.02 Results of Operations and Financial Condition | 2.02 On August 7, 2025, scPharmaceuticals Inc. announced its financial results for the quarter ended June 30, 2025. | d96876d8k.htm |
| 2025-06-09 | 8-K | 2025-06-03 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 On June 3, 2025, scPharmaceuticals Inc. (the “Company”) held its Annual Meeting of Stockholders. | d67338d8k.htm |
| 2025-05-14 | 8-K | 2025-05-14 | 2.02 Results of Operations and Financial Condition | 2.02 On May 14, 2025, scPharmaceuticals Inc. announced its financial results for the quarter ended March 31, 2025. | d830657d8k.htm |
| 2025-03-19 | 8-K | 2025-03-19 | 2.02 Results of Operations and Financial Condition | 2.02 On March 19, 2025, scPharmaceuticals Inc. announced its financial results for the quarter and year ended December 31, 2024. | d901463d8k.htm |
| 2025-01-10 | 8-K | 2025-01-10 | 2.02 Results of Operations and Financial Condition; 8.01 Other Events | 2.02 The information contained in Item 2.02 of this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly provided by specific reference in such a filing. | d886285d8k.htm |
| 2024-12-11 | 8-K | 2024-12-11 | 7.01 Regulation FD Disclosure | 7.01 On December 11, 2024, scPharmaceuticals Inc. (the “Company”) disclosed it has recently observed variability during shelf-life testing in one lot of the SCP-111 Combination Product. | d903999d8k.htm |
| 2024-11-13 | 8-K | 2024-11-13 | 2.02 Results of Operations and Financial Condition | 2.02 On November 13, 2024, scPharmaceuticals Inc. announced its financial results for the quarter ended September 30, 2024. | d860903d8k.htm |
| 2024-08-14 | 8-K | 2024-08-14 | 2.02 Results of Operations and Financial Condition | 2.02 On August 14, 2024, scPharmaceuticals Inc. announced its financial results for the quarter ended June 30, 2024. | d857974d8k.htm |
| 2024-08-13 | 8-K | 2024-08-12 | 8.01 Other Events | 8.01 On August 12, 2024, scPharmaceuticals Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Leerink Partners LLC and TD Securities (USA) LLC, as representatives of the several underwriters named in Schedule A thereto (collectively, the “Underwriters”), relating to an underwritten offering of 12,000,000 shares (the “Shares”) of the Company’s common stock, $0.0001 par value per share (the “Common Stock”), and, in lieu of Common Stock to select investors, pre-funded warrants (the “Pre-funded Warrants”) to purchase 500,000 shares of Common Stock (the “Offering”). | d875997d8k.htm |
| 2024-08-12 | 8-K | 2024-08-09 | 1.01 Entry into a Material Definitive Agreement; 1.02 Termination of a Material Definitive Agreement; 2.02 Results of Operations and Financial Condition; 3.02 Unregistered Sales of Equity Securities; 8.01 Other Events | 1.01 Entry into a Material Definitive Agreement. 1.02 The information included in Item 1.01 of this Current Report on Form 8-K concerning the prepayment and termination of the Existing Credit Agreement is hereby incorporated by reference in this Item 1.02. 2.02 The Company is currently finalizing its financial quarterly closing process for the three months ended June 30, 2024. 3.02 The information contained above in Item 1.01 relating to the Warrant is incorporated by reference into this Item 3.02 in its entirety. 8.01 On August 12, 2024, the Company announced positive topline results from the pharmacokinetic (PK) study of SCP-111, an investigational, low volume, pH neutral formulation of furosemide administered via an autoinjector as an alternative to the current on-body infusor used with FUROSCIX. | d755257d8k.htm |
| 2024-06-14 | 8-K | 2024-06-11 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 On June 11, 2024, scPharmaceuticals Inc. (the “Company”) held its Annual Meeting of Stockholders. | d810269d8k.htm |
| 2024-05-16 | 8-K | 2024-05-16 | 8.01 Other Events | 8.01 On May 16, 2024, scPharmaceuticals Inc. announced that, from launch through March 31, 2024, there have been approximately 47,000 total FUROSCIX doses written by around 2,200 unique prescribers and, of these, approximately 24,000 FUROSCIX doses had been filled. | d813751d8k.htm |
| 2024-05-14 | 8-K | 2024-05-14 | 2.02 Results of Operations and Financial Condition | 2.02 On May 14, 2024, scPharmaceuticals Inc. announced its financial results for the quarter ended March 31, 2024. | d810552d8k.htm |
| 2024-03-13 | 8-K | 2024-03-13 | 2.02 Results of Operations and Financial Condition | 2.02 On March 13, 2024, scPharmaceuticals Inc. announced its financial results for the quarter and year ended December 31, 2023. | d742679d8k.htm |
| 2024-01-04 | 8-K | 2024-01-04 | 2.02 Results of Operations and Financial Condition; 8.01 Other Events | 2.02 The information contained in Item 2.02 of this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly provided by specific reference in such a filing. 8.01 On January 4, 2024, the Company announced preliminary unaudited fourth quarter 2023 net FUROSCIX revenue in a range of $5.9 million to $6.1 million, representing sequential growth of 55% to 61% over $3.8 million net FUROSCIX revenue reported for the third quarter of 2023. | d106754d8k.htm |
| 2023-11-08 | 8-K | 2023-11-08 | 2.02 Results of Operations and Financial Condition | 2.02 On November 8, 2023, scPharmaceuticals Inc. announced its financial results for the quarter ended September 30, 2023. | d579935d8k.htm |
| 2023-09-20 | 8-K | 2023-09-14 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | d547644d8k.htm |
| 2023-08-10 | 8-K | 2023-08-10 | 2.02 Results of Operations and Financial Condition | 2.02 On August 10, 2023, scPharmaceuticals Inc. announced its financial results for the quarter ended June 30, 2023. | d345266d8k.htm |
| 2023-06-08 | 8-K | 2023-06-06 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 On June 6, 2023, scPharmaceuticals Inc. (the “Company”) held its Annual Meeting of Stockholders. | d492887d8k.htm |
| 2023-06-07 | 8-K | 2023-06-07 | 8.01 Other Events | 8.01 On June 7, 2023, in connection with a corporate update to be presented at a healthcare conference, scPharmaceuticals Inc. will report that, during February 2023, there were approximately 40 total FUROSCIX prescriptions written, consisting of approximately 160 total FUROSCIX doses, and of these, approximately 10 FUROSCIX prescriptions, consisting of approximately 40 total FUROSCIX doses (an average of 4 doses per filled prescription), had been shipped. | d516650d8k.htm |
| 2023-05-10 | 8-K | 2023-05-10 | 2.02 Results of Operations and Financial Condition | 2.02 On May 10, 2023, scPharmaceuticals Inc. announced its financial results for the quarter ended March 31, 2023. | d476379d8k.htm |
| 2023-03-22 | 8-K | 2023-03-22 | 2.02 Results of Operations and Financial Condition | 2.02 On March 22, 2023, scPharmaceuticals Inc. announced its financial results for the quarter and year ended December 31, 2022. | d444874d8k.htm |
| 2023-03-10 | 8-K | 2023-03-10 | 8.01 Other Events | 8.01 scPharmaceuticals Inc. discloses that it has two deposit accounts at Silicon Valley Bank, each with a balance of equal to or less than $250,000 as of March 10, 2023. | d483112d8k.htm |
| 2022-12-19 | 8-K | 2022-12-15 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On December 15, 2022, the Board of Directors (the “Board”) of scPharmaceuticals Inc. (the “Company”) appointed Rachael Nokes, the Company’s former Senior Vice President of Finance, to serve as the Company’s Chief Financial Officer, effective immediately, in addition to her role as the Company’s Treasurer. | d402136d8k.htm |
| 2022-11-23 | 8-K | 2022-11-22 | 8.01 Other Events | 8.01 On November 22, 2022, scPharmaceuticals Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with SVB Securities LLC and Cowen and Company, LLC, as representatives of the several underwriters named in Schedule A thereto (collectively, the “Underwriters”), relating to an underwritten offering of 6,620,000 shares (the “Shares”) of the Company’s common stock, $0.0001 par value per share (the “Common Stock”), and, in lieu of Common Stock to a certain investor, a pre-funded warrant (the “Pre-funded Warrant”) to purchase 2,905,000 shares of Common Stock (the “Offering”). | d240360d8k.htm |
| 2022-11-09 | 8-K | 2022-11-09 | 2.02 Results of Operations and Financial Condition | 2.02 On November 9, 2022, scPharmaceuticals Inc. announced its financial results for the quarter ended September 30, 2022. | d395351d8k.htm |
| 2022-10-14 | 8-K | 2022-10-10 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 3.02 Unregistered Sales of Equity Securities; 8.01 Other Events | 1.01 Entry into a Material Definitive Agreement. 2.03 The information set forth in Item 1.01 of this Current Report on Form 8-K is incorporated by reference into this Item 2.03. 3.02 The information set forth in Item 1.01 of this Current Report on Form 8-K is incorporated by reference into this Item 3.02. 8.01 On October 10, 2022, the Company announced that the U.S. Food and Drug Administration (the “FDA”) has approved FUROSCIX® (furosemide injection), a proprietary formulation of furosemide delivered via West Pharmaceutical Services, Inc.’s on-body infusor for the treatment of congestion due to fluid overload in adults with New York Heart Association Class II/III chronic heart failure. | d329625d8k.htm |
| 2022-08-09 | 8-K | 2022-08-09 | 2.02 Results of Operations and Financial Condition | 2.02 On August 9, 2022, scPharmaceuticals Inc. (the “Company”) announced its financial results for the second quarter ended June 30, 2022. | d308621d8k.htm |
| 2022-07-12 | 8-K | 2022-07-12 | 8.01 Other Events | 8.01 On July 12, 2022, scPharmaceuticals Inc. issued a press release announcing results from its AT HOME-HF Pilot study. | d376227d8k.htm |
| 2022-06-15 | 8-K | 2022-06-14 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 The 2022 Annual Meeting of Stockholders (the “Annual Meeting”) of scPharmaceuticals Inc. (the “Company”) was held on June 14, 2022. | d307287d8k.htm |
| 2022-05-16 | 8-K | 2022-05-16 | 2.02 Results of Operations and Financial Condition | 2.02 On May 16, 2022, scPharmaceuticals Inc. (the “Company”) announced its financial results for the first quarter ended March 31, 2022. | d304459d8k.htm |
| 2022-05-16 | 8-K | 2022-05-16 | 8.01 Other Events | 8.01 On May 16, 2022, scPharmaceuticals Inc. (the “Company”) issued a press release announcing that the U.S. Food and Drug Administration (the “FDA”) has accepted the Company’s New Drug Application (“NDA”) resubmission for its product candidate, FUROSCIX®, a proprietary formulation of furosemide delivered via an on-body infusor for the treatment of congestion in patients with worsening heart failure. | d297716d8k.htm |
| 2022-04-12 | 8-K | 2022-04-11 | 8.01 Other Events | 8.01 On April 11, 2022, scPharmaceuticals Inc. (the “Company”) issued a press release announcing that it has resubmitted its New Drug Application (“NDA”) to the U.S. Food and Drug Administration (the “FDA”) seeking marketing approval of its product candidate, FUROSCIX® (furosemide injection), for the treatment of decompensated heart failure. | d325289d8k.htm |
| 2022-03-22 | 8-K | 2022-03-22 | 2.02 Results of Operations and Financial Condition | 2.02 On March 22, 2022, scPharmaceuticals Inc. announced its financial results for the fourth quarter and fiscal year ended December 31, 2021. | d314189d8k.htm |
| 2021-11-09 | 8-K | 2021-11-09 | 2.02 Results of Operations and Financial Condition | 2.02 On November 9, 2021, scPharmaceuticals Inc. announced its financial results for the third quarter ended September 30, 2021. | d257443d8k.htm |
| 2021-09-10 | 8-K | 2021-09-10 | 8.01 Other Events | 8.01 On September 10, 2021, scPharmaceuticals Inc. issued a press release announcing additional results from its FREEDOM-HF study to be presented at the Heart Failure Society of America Annual Scientific Meeting 2021. | d228016d8k.htm |
| 2021-08-11 | 8-K | 2021-08-11 | 2.02 Results of Operations and Financial Condition | 2.02 On August 11, 2021, scPharmaceuticals Inc. announced its financial results for the second quarter ended June 30, 2021. | d180808d8k.htm |
| 2021-07-14 | 8-K | 2021-07-13 | 8.01 Other Events | 8.01 On July 13, 2021, scPharmaceuticals Inc. (the “Company”) announced positive top-line results from its FREEDOM-HF study. | d203690d8k.htm |
| 2021-07-01 | 8-K | 2021-07-01 | 8.01 Other Events | 8.01 On July 1, 2021, scPharmaceuticals Inc. (the “Company”) issued a press release announcing the results of a Type C meeting with the U.S. Food and Drug Administration (the “FDA”) regarding the requirements for resubmission of the Company’s FUROSCIX® New Drug Application. | d235024d8k.htm |
| 2021-06-09 | 8-K | 2021-06-08 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 The 2021 Annual Meeting of Stockholders (the “Annual Meeting”) of scPharmaceuticals Inc. (the “Company”) was held on June 8, 2021. | d176720d8k.htm |
| 2021-05-12 | 8-K | 2021-05-12 | 2.02 Results of Operations and Financial Condition | 2.02 On May 12, 2021, scPharmaceuticals Inc. announced its financial results for the first quarter ended March 31, 2021. | d287809d8k.htm |
| 2021-03-23 | 8-K | 2021-03-23 | 2.02 Results of Operations and Financial Condition | 2.02 On March 23, 2021, scPharmaceuticals Inc. announced its financial results for the fourth quarter and fiscal year ended December 31, 2020. | d49692d8k.htm |
| 2021-03-12 | 8-K | 2021-03-09 | 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year | 5.03 On March 9, 2021, the Board of Directors (the “Board”) of scPharmaceuticals Inc. (the “Company”) amended the Company’s Amended and Restated By-laws, as amended, in order to amend Section 8 of Article VI to designate the federal district courts of the United States of America as the exclusive jurisdiction for any litigation arising under the Securities Act of 1933, as amended (the “By-law Amendment”). | d151721d8k.htm |
| 2021-02-23 | 8-K | 2021-02-23 | 2.02 Results of Operations and Financial Condition; 8.01 Other Events | 2.02 On February 23, 2021, scPharmaceuticals Inc. (the “Company”) issued a press release which included certain unaudited preliminary financial results for the fourth quarter and fiscal year ended December 31, 2020 (the “Press Release”). 8.01 On February 23, 2021, the Company announced the results of a Type A meeting with the U.S. Food and Drug Administration (the “FDA”) regarding the Company’s FUROSCIX® New Drug Application (“NDA”). | d138732d8k.htm |
| 2021-02-17 | 8-K | 2021-02-16 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On February 16, 2021, upon the recommendation of its Nominating and Corporate Governance Committee, the Board of Directors (the “Board”) of scPharmaceuticals Inc. (the “Company”) appointed William T. Abraham, MD to join the Board, effective as of February 16, 2021. | d143096d8k.htm |
| 2020-12-07 | 8-K | 2020-12-03 | 8.01 Other Events | 8.01 On December 7, 2020, scPharmaceuticals Inc. (the “Company”) issued a press release announcing that it had received a complete response letter (the “CRL”) from the U.S. Food and Drug Administration (the “FDA”) on December 3, 2020 for the Company’s New Drug Application (the “NDA”) for its product candidate, FUROSCIX®, a novel formulation of furosemide delivered via an on-body infusor under development for the treatment of congestion in patients with worsening heart failure. | d59025d8k.htm |
| 2020-12-04 | 8-K | 2020-12-03 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On December 3, 2020, Mason W. Freeman, M.D. informed the Board of Directors (the “Board”) of scPharmaceuticals Inc. (the “Company”) of his resignation as a member of the Board and all committees of the Board, effective as of December 15, 2020. | d131020d8k.htm |
| 2020-11-16 | 8-K | 2020-11-16 | 2.02 Results of Operations and Financial Condition | 2.02 On November 16, 2020, scPharmaceuticals Inc. announced its financial results for the third quarter ended September 30, 2020. | d10699d8k.htm |
| 2020-08-20 | 8-K | 2020-08-15 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | d84607d8k.htm |
| 2020-08-13 | 8-K | 2020-08-13 | 2.02 Results of Operations and Financial Condition | 2.02 On August 13, 2020, scPharmaceuticals Inc. announced its financial results for the second quarter ended June 30, 2020. | d892982d8k.htm |
| 2020-07-27 | 8-K | 2020-07-27 | 8.01 Other Events | 8.01 On July 27, 2020, scPharmaceuticals Inc. (the “Company”) issued a press release announcing that the U.S. Food and Drug Administration (the “FDA”) has accepted the Company’s New Drug Application (“NDA”) resubmission for its product candidate, FUROSCIX® , a proprietary, subcutaneously delivered furosemide solution outpatient alternative for the treatment of worsening heart failure due to congestion. | d85896d8k.htm |
| 2020-07-10 | 8-K | 2020-07-06 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On July 6, 2020, Dorothy Coleman informed the Board of Directors (the “Board”) of scPharmaceuticals Inc. (the “Company”) of her resignation as a member of the Board and all committees of the Board, effective as of July 6, 2020. | d80734d8k.htm |
| 2020-06-10 | 8-K | 2020-06-09 | 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year; 5.07 Submission of Matters to a Vote of Security Holders | 5.03 On June 9, 2020, the Board amended the Company’s Amended and Restated By-laws in order to amend Section 8 of Article VI to designate the United States District Court for the District of Massachusetts as the exclusive jurisdiction for any litigation arising under the Securities Act of 1933, as amended (the “By-law Amendment”). 5.07 The 2020 Annual Meeting of Stockholders (the “Annual Meeting”) of scPharmaceuticals Inc. (the “Company”) was held on June 9, 2020. | d942891d8k.htm |
| 2020-05-22 | 8-K | 2020-05-22 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | d925586d8k.htm |
| 2020-05-12 | 8-K | 2020-05-12 | 2.02 Results of Operations and Financial Condition | 2.02 On May 12, 2020, scPharmaceuticals Inc. announced its financial results for the first quarter ended March 31, 2020. | d912542d8k.htm |
| 2020-03-24 | 8-K | 2020-03-24 | 2.02 Results of Operations and Financial Condition | 2.02 On March 24, 2020, scPharmaceuticals Inc. announced its financial results for the fourth quarter and fiscal year ended December 31, 2019. | d895467d8k.htm |
| 2019-11-12 | 8-K | 2019-11-12 | 2.02 Results of Operations and Financial Condition | 2.02 On November 12, 2019, scPharmaceuticals Inc. announced its financial results for the third quarter ended September 30, 2019. | d831200d8k.htm |
| 2019-09-18 | 8-K | 2019-09-17 | 1.01 Entry into a Material Definitive Agreement; 1.02 Termination of a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 7.01 Regulation FD Disclosure | 1.01 Entry into a Material Definitive Agreement. 1.02 The information in Item 1.01 above with respect to the Original Loan Agreement is incorporated by reference into this Item 1.02. 2.03 The information contained in Item 1.01 is hereby incorporated by reference in this Item 2.03. 7.01 On September 18, 2019, the Company and Lenders issued a press release announcing the execution of the Loan Agreement. | d804440d8k.htm |
| 2019-08-23 | 8-K | 2019-08-23 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | d753470d8k.htm |
| 2019-08-07 | 8-K | 2019-08-07 | 2.02 Results of Operations and Financial Condition | 2.02 On August 7, 2019, scPharmaceuticals Inc. announced its financial results for the first quarter ended June 30, 2019. | d758732d8k.htm |
| 2019-06-20 | 8-K | 2019-06-18 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 The 2019 Annual Meeting of Stockholders (the “Annual Meeting”) of scPharmaceuticals Inc. (the “Company”) was held on June 18, 2019. | d766963d8k.htm |
| 2019-06-04 | 8-K | 2019-05-31 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | d751265d8k.htm |
| 2019-05-08 | 8-K | 2019-05-08 | 2.02 Results of Operations and Financial Condition | 2.02 On May 8, 2019, scPharmaceuticals Inc. announced its financial results for the first quarter ended March 31, 2019. | d741675d8k.htm |
| 2019-03-21 | 8-K | 2019-03-21 | 2.02 Results of Operations and Financial Condition | 2.02 On March 21, 2019, scPharmaceuticals Inc. announced its financial results for the fiscal quarter and year ended December 31, 2018. | d725308d8k.htm |
| 2019-01-29 | 8-K | 2019-01-28 | 1.01 Entry into a Material Definitive Agreement; 1.02 Termination of a Material Definitive Agreement; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 7.01 Regulation FD Disclosure; 8.01 Other Events | 1.01 Entry into a Material Definitive Agreement. 1.02 On January 29, 2019, the Company issued to Sensile Medical AG (“Sensile”) a notice of termination for business reasons under the License Agreement, dated as of June 29, 2015, as subsequently amended, by and between the Company and Sensile (the “License Agreement”). 5.02 On January 28, 2019, the Company and Troy Ignelzi, the Company’s Chief Financial Officer (and principal financial and accounting officer) agreed to end Mr. Ignelzi’s employment with the Company and its subsidiaries effective February 28, 2019 (the “Effective Date”). 7.01 On January 29, 2019, the Company issued a press release announcing its entry into the West Development Agreement. 8.01 As previously disclosed, on June 11, 2018, the Company received a complete response letter (“CRL”) from the U.S. Food and Drug Administration regarding its New Drug Application (the “NDA”) under section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act for FUROSCIX Infusor (furosemide), 80 mg/10 mL, drug-device combination product. | d700664d8k.htm |
| 2019-01-03 | 8-K | 2019-01-03 | 8.01 Other Events | 8.01 scPharmaceuticals Inc. (the “Company”) is filing this Current Report on Form 8-K to recast certain historical financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017 (the “2017 Form 10-K”), originally filed with the Securities and Exchange Commission (“SEC”) on March 21, 2018, to reflect the Company’s early adoption of ASU 2016-02, Leases (Topic 842) (“ASC 842”), with retrospective application to January 1, 2016. | d678467d8k.htm |
| 2018-11-27 | 8-K | 2018-11-21 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant | 1.01 Entry into a Material Definitive Agreement. 2.03 The information contained in Item 1.01 of this Current Report on Form 8-K is hereby incorporated by reference in this Item 2.03. | d657424d8k.htm |
| 2018-11-13 | 8-K | 2018-11-13 | 2.02 Results of Operations and Financial Condition | 2.02 On November 13, 2018, scPharmaceuticals Inc. announced its financial results for its third quarter ended September 30, 2018. | d634752d8k.htm |
| 2018-10-22 | 8-K | 2018-10-18 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 Effective October 19, 2018, Abraham Ceesay departed as Chief Operating Officer of scPharmaceuticals Inc. (the “Company”). | d637039d8k.htm |
| 2018-10-18 | 8-K | 2018-10-16 | 8.01 Other Events | 8.01 As previously disclosed, on June 11, 2018, scPharmaceuticals Inc. (the “Company”) received a complete response letter (“CRL”) from the U.S. Food and Drug Administration (the “FDA”) following the FDA’s review of a New Drug Application submitted by the Company under section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act for FUROSCIX™ Infusor (furosemide), 80 mg/10 mL, drug-device combination product. | d621202d8k.htm |
| 2018-09-07 | 8-K | 2018-08-31 | 8.01 Other Events | 8.01 On August 31, 2018, scPharmaceuticals Inc. (the “Company”) was informed by the National Heart and Lung Institute (the “NHLBI”) of its decision to close the investigator-sponsored Subcutaneous Furosemide in Acute Decompensated Heart Failure (SUB-Q-HF) study. | d619926d8k.htm |
| 2018-08-14 | 8-K | 2018-08-14 | 2.02 Results of Operations and Financial Condition | 2.02 On August 14, 2018, scPharmaceuticals Inc. announced its financial results for its second quarter ended June 30, 2018. | d605648d8k.htm |
| 2018-07-24 | 8-K | 2018-07-20 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 7.01 Regulation FD Disclosure | 5.02 On July 20, 2018, Kush M. Parmar, M.D., Ph.D., informed the Board of Directors (the “Board”) of scPharmaceuticals Inc. (the “Company”) of his resignation as a director and as a member of the Audit Committee and the Compensation Committee of the Board. 7.01 On July 24, 2018, the Company issued a press release announcing Ms. Baylor-Henry and Dr. Freeman’s election to the Board. | d574014d8k.htm |
| 2018-06-20 | 8-K | 2018-06-19 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 The 2018 Annual Meeting of Stockholders (the “Annual Meeting”) of scPharmaceuticals Inc. (the “Company”) was held on June 19, 2018. | d770972d8k.htm |
| 2018-06-15 | 8-K | 2018-06-15 | 8.01 Other Events | 8.01 As previously disclosed, on June 11, 2018, scPharmaceuticals Inc. (the “Company”) received a complete response letter (“CRL”) from the U.S. Food and Drug Administration (the “FDA”) regarding its New Drug Application (the “NDA”) under section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act for Furoscix™ Infusor (furosemide), 80 mg/10 mL, drug-device combination product. | d609324d8k.htm |
| 2018-06-13 | 8-K | 2018-06-11 | 8.01 Other Events | 8.01 On August 23, 2017, scPharmaceuticals Inc. (the “Company”) submitted to the U.S. Food and Drug Administration (the “FDA”) a New Drug Application (the “NDA”) under section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act for Furoscix™ Infusor (furosemide), 80 mg/10 mL, drug-device combination product. | d607191d8k.htm |
| 2018-05-31 | 8-K | 2018-05-30 | 8.01 Other Events | 8.01 On August 23, 2017, scPharmaceuticals Inc. (the “Company”) submitted to the U.S. Food and Drug Administration (the “FDA”) a New Drug Application (the “NDA”) under section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act for Furoscix™ Infusor (furosemide), 80 mg/10 mL, drug-device combination product. | d588599d8k.htm |
| 2018-05-07 | 8-K | 2018-05-07 | 2.02 Results of Operations and Financial Condition | 2.02 On May 7, 2018, scPharmaceuticals Inc. announced its financial results for the fiscal quarter March 31, 2018. | d585395d8k.htm |
| 2018-03-21 | 8-K | 2018-03-20 | 2.02 Results of Operations and Financial Condition | 2.02 On March 20, 2018, scPharmaceuticals Inc. announced its financial results for the fiscal quarter and year ended December 31, 2017. | d553906d8k.htm |
| 2017-11-21 | 8-K | 2017-11-21 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year | 5.02 As previously disclosed in the Registration Statement on Form S-1 (File No. 333-221077) (the “Registration Statement”) of scPharmaceuticals Inc. (the “Company”), on November 21, 2017 and in connection with the consummation of the initial public offering (the “IPO”) of shares of common stock of the Company, Jonathan Silverstein resigned from the Company’s board of directors (the “Board”). 5.03 As previously disclosed in the Registration Statement, on November 21, 2017 and in connection with the consummation of the IPO, the Company filed a second amended and restated certificate of incorporation (the “Restated Certificate”) with the Secretary of State of the State of Delaware. | d488218d8k.htm |